支气管内超声引导活检来源肺癌模型:精准治疗平台
本研究利用175例支气管内超声(EBUS)标本建立患者来源类器官(PDO)和患者来源异种移植(PDX)模型,成功建立20个EBUS类器官(6个EBUS-PDO和14个EBUS-xenograft来源类器官)。稳定类器官模型在病理、外显子组和转录组上与亲本样本高度一致,且药物反应模式与对应患者一致,并发现曲美替尼对罕见MAP2K1 K57N突变具有强活性。
要点
- EBUS标本可建立稳定的肺癌类器官和PDX模型。
- 模型在基因和病理特征上与患者肿瘤高度一致。
- 模型药物反应与患者临床反应一致,可用于治疗研究。
核心结论
- EBUS-PDO和EBUS-xenograft来源类器官是晚期肺癌患者建立稳定类器官的良好选择,模型与患者肿瘤的遗传和病理特征及治疗反应一致,支持其用于新治疗研究。
研究设计与样本
- 研究使用175例EBUS标本建立PDO和PDX,并将传代数≥10的稳定类器官用于基因组、转录组和病理评估。
主要发现
- 成功建立20个EBUS类器官,包括6个EBUS-PDO和14个EBUS-xenograft来源类器官。
- 稳定类器官模型验证了癌细胞富集和病理评估,病理、外显子组和转录组分析与亲本样本高度相关。
- EBUS类器官和PDX的药物反应模式与对应患者一致。
- 对EBUS类器官进行药物筛选发现曲美替尼对罕见MAP2K1 K57N突变具有强活性。
临床怎么用
- EBUS活检标本可用于建立患者来源类器官和PDX模型,以支持精准治疗研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endobronchial ultrasound-guided transbronchial needle aspiration is used for clinical diagnosis and staging in patients with lung cancer. Nevertheless, establishing patient-derived preclinical models using needle biopsy samples remains challenging. This study describes the establishment and utility of patient-derived organoid (PDO) from endobronchial ultrasound-guided (EBUS) specimens and EBUS patient-derived xenograft (PDX). METHODS: A total of 175 EBUS specimens were used to establish PDO and PDX. "Stable establishment" organoids with passage numbers of 10 or greater were used for genomic, transcriptome, and pathologic assessment. Drug sensitivity of EBUS organoids and PDX tumors were compared with those of the matched patient. Drug screening was performed using stably established organoid models. RESULTS: We successfully established a total of 20 EBUS organoids: six EBUS-PDOs and 14 EBUS-xenograft derived organoids. These stable cancer organoid models were validated for cancer cell enrichment and pathologic assessment. Pathologic findings, exome, and transcriptome analysis found a high correlation between EBUS organoids and parental samples. EBUS organoids and PDX indicated consistent drug response patterns with their corresponding patients. A drug screening conducted on an EBUS organoid led to the discovery of potent activity of trametinib to a rare MAP2K1 K57N mutation. CONCLUSIONS: EBUS-PDO and -xenograft‒derived organoids are good options to generate stable organoids in patients with advanced stage lung cancer. The models were consistent with the genetic and pathologic features of patient tumors, and the patient's responses to treatment, supporting their utility for novel therapeutic research.
引用
- Koga T, Ogawa H, Radulovich N, et al. Endobronchial Ultrasound-Guided Biopsy-Derived Lung Cancer Models: A Platform for Precision Therapy. J Thorac Oncol. 2026. PMID: 42055160. doi:10.1016/j.jtho.2026.103893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。